Jacobs Levy Equity Management, Inc Rubius Therapeutics, Inc. Transaction History

Jacobs Levy Equity Management, Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 15, 2022	BUY	$0.46 - $1.29 $250,349 - $702,067	544,238 New	544,238 $236,000
Q1 2022 May 16, 2022	SELL	$4.25 - $10.4 $54,276 - $132,818	-12,771 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$9.68 - $17.74 $127,872 - $234,345	-13,210 Reduced 50.84%	12,771 $124,000
Q2 2021 Aug 16, 2021	SELL	$22.26 - $28.43 $279,696 - $357,222	-12,565 Reduced 32.6%	25,981 $634,000
Q1 2021 May 17, 2021	SELL	$8.02 - $32.01 $2.86 Million - $11.4 Million	-356,363 Reduced 90.24%	38,546 $1.02 Million
Q4 2020 Feb 16, 2021	SELL	$4.23 - $8.73 $32,342 - $66,749	-7,646 Reduced 1.9%	394,909 $3 Million
Q3 2020 Nov 16, 2020	BUY	$4.65 - $6.25 $142,708 - $191,812	30,690 Added 8.25%	402,555 $2.02 Million
Q2 2020 Aug 17, 2020	BUY	$4.01 - $6.88 $1.49 Million - $2.56 Million	371,865 New	371,865 $2.22 Million

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.